Technical Analysis for BLUE - bluebird bio, Inc.

Grade Last Price % Change Price Change
D 1.44 1.41% 0.02
BLUE closed up 1.41 percent on Monday, March 18, 2024, on 79 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 27
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Doji - Bearish? Reversal 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Bullish Engulfing Bullish 1.41%
Crossed Above 20 DMA Bullish 1.41%
Pocket Pivot Bullish Swing Setup 1.41%
Stochastic Reached Oversold Weakness 1.41%
Wide Bands Range Expansion 1.41%
Oversold Stochastic Weakness 1.41%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakout about 15 hours ago
Up 5% about 16 hours ago
Down 3% about 17 hours ago
Fell Below 20 DMA about 17 hours ago
Fell Below 10 DMA about 17 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

bluebird bio, Inc. Description

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on the development, manufacture, and marketing of therapies to treat various human diseases. Its product candidates include Lenti-D to treat patients with childhood cerebral adrenoleukodystrophy (ALD), a hereditary neurological disorder, as well as for the treatment of adult cerebral ALD; and CAR T cells products for treating oncology diseases. The company's product candidates also comprise LentiGlobin vector for the treatment of ß-thalassemia, a hereditary blood disorder; and sickle cell diseases. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Rare Diseases Medical Genetics Dystrophy Human Diseases Summit Childhood Genetic Genealogy Sickle Cell Disease Thalassemia Iglo Leukodystrophy Oncology Diseases

Is BLUE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 5.53
52 Week Low 0.879
Average Volume 10,036,153
200-Day Moving Average 2.78
50-Day Moving Average 1.26
20-Day Moving Average 1.41
10-Day Moving Average 1.41
Average True Range 0.17
RSI (14) 53.05
ADX 24.45
+DI 25.27
-DI 15.10
Chandelier Exit (Long, 3 ATRs) 1.41
Chandelier Exit (Short, 3 ATRs) 1.51
Upper Bollinger Bands 1.73
Lower Bollinger Band 1.08
Percent B (%b) 0.55
BandWidth 46.36
MACD Line 0.03
MACD Signal Line 0.03
MACD Histogram -0.0017
Fundamentals Value
Market Cap 277.55 Million
Num Shares 193 Million
EPS -0.63
Price-to-Earnings (P/E) Ratio -2.29
Price-to-Sales 9.32
Price-to-Book 0.89
PEG Ratio 0.32
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.70
Resistance 3 (R3) 1.71 1.63 1.66
Resistance 2 (R2) 1.63 1.56 1.62 1.64
Resistance 1 (R1) 1.53 1.52 1.49 1.53 1.63
Pivot Point 1.45 1.45 1.43 1.45 1.45
Support 1 (S1) 1.36 1.38 1.32 1.35 1.25
Support 2 (S2) 1.28 1.34 1.27 1.24
Support 3 (S3) 1.18 1.28 1.22
Support 4 (S4) 1.18